PUBLISHER: TechNavio | PRODUCT CODE: 2126065
PUBLISHER: TechNavio | PRODUCT CODE: 2126065
Global Autoimmune Hemolytic Anemia Therapeutics Market 2026-2030
The global autoimmune hemolytic anemia therapeutics market is forecasted to grow by USD 349322.8 thousand during 2025-2030, accelerating at a CAGR of 9.8% during the forecast period. The report on the global autoimmune hemolytic anemia therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising global prevalence of refractory autoimmune hemolytic conditions drives demand, accelerated regulatory incentives for rare hematological treatments boost pipeline investments, expansion of precision medicine paradigms enables targeted complement pathway inhibition.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 9.5% |
| CAGR | 9.8% |
| Incremental Value | $349322.8 thousand |
Technavio's global autoimmune hemolytic anemia therapeutics market is segmented as below:
By Product
- Corticosteroids
- Monoclonal antibodies
- Others
By Route Of Administration
- Oral
- Topical
- Others
By Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Online
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the strategic shift toward targeted complement pathway inhibitors reshapes standard paradigms as one of the prime reasons driving the global autoimmune hemolytic anemia therapeutics market growth during the next few years. Also, rising strategic collaborations between biotechnology leaders and academic research centers and integration of digital biomarkers and remote monitoring tools enhances trial efficiency will lead to sizable demand in the market.
The report on the global autoimmune hemolytic anemia therapeutics market covers the following areas:
- Global autoimmune hemolytic anemia therapeutics market sizing
- Global autoimmune hemolytic anemia therapeutics market forecast
- Global autoimmune hemolytic anemia therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global autoimmune hemolytic anemia therapeutics market vendors that include Annexon Biosciences Inc., Apellis Pharmaceuticals Inc., argenx SE, AstraZeneca Plc, Aurinia Pharmaceuticals Inc., F. Hoffmann La Roche Ltd., Hutchison China Ltd., IASO Biotherapeutics, Incyte Corp., Johnson and Johnson, Novartis AG, Nurix Therapeutics Inc., Recordati S.p.A, Rigel Pharmaceuticals Inc., Sanofi SA, Vertex Pharmaceuticals Inc.. Also, the global autoimmune hemolytic anemia therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Product
- Executive Summary - Chart on Market Segmentation by Route of Administration
- Executive Summary - Chart on Market Segmentation by Distribution Channel
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Autoimmune Hemolytic Anemia Therapeutics Market 2020 - 2024
- Historic Market Size - Data Table on Global Autoimmune Hemolytic Anemia Therapeutics Market 2020 - 2024 ($ thousand)
- 5.2 Product segment analysis 2020 - 2024
- Historic Market Size - Product Segment 2020 - 2024 ($ thousand)
- 5.3 Route of Administration segment analysis 2020 - 2024
- Historic Market Size - Route of Administration Segment 2020 - 2024 ($ thousand)
- 5.4 Distribution Channel segment analysis 2020 - 2024
- Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ thousand)
- 5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ thousand)
- 5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ thousand)
6 Qualitative Analysis
- 6.1 Impact of AI on global autoimmune hemolytic anemia therapeutics market
- 6.2 Impact of geopolitical conflicts on global autoimmune hemolytic anemia therapeutics market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by Product
- 8.1 Market segments
- 8.2 Comparison by Product
- 8.3 Corticosteroids - Market size and forecast 2025-2030
- 8.4 Monoclonal antibodies - Market size and forecast 2025-2030
- 8.5 Others - Market size and forecast 2025-2030
- 8.6 Market opportunity by Product
- Market opportunity by Product ($ thousand)
9 Market Segmentation by Route of Administration
- 9.1 Market segments
- 9.2 Comparison by Route of Administration
- 9.3 Oral - Market size and forecast 2025-2030
- 9.4 Topical - Market size and forecast 2025-2030
- 9.5 Others - Market size and forecast 2025-2030
- 9.6 Market opportunity by Route of Administration
- Market opportunity by Route of Administration ($ thousand)
10 Market Segmentation by Distribution Channel
- 10.1 Market segments
- 10.2 Comparison by Distribution Channel
- 10.3 Hospital pharmacy - Market size and forecast 2025-2030
- 10.4 Retail pharmacy - Market size and forecast 2025-2030
- 10.5 Online - Market size and forecast 2025-2030
- 10.6 Market opportunity by Distribution Channel
- Market opportunity by Distribution Channel ($ thousand)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
- 12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 Germany - Market size and forecast 2025-2030
- 12.4.2 UK - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
- 12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 China - Market size and forecast 2025-2030
- 12.5.2 Japan - Market size and forecast 2025-2030
- 12.5.3 South Korea - Market size and forecast 2025-2030
- 12.5.4 India - Market size and forecast 2025-2030
- 12.5.5 Taiwan - Market size and forecast 2025-2030
- 12.5.6 Singapore - Market size and forecast 2025-2030
- 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Brazil - Market size and forecast 2025-2030
- 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.3 South Africa - Market size and forecast 2025-2030
- 12.6.4 Argentina - Market size and forecast 2025-2030
- 12.6.5 UAE - Market size and forecast 2025-2030
- 12.6.6 Israel - Market size and forecast 2025-2030
- 12.6.7 Egypt - Market size and forecast 2025-2030
- 12.6.8 Chile - Market size and forecast 2025-2030
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ thousand)
- Data Tables on Market opportunity by geography ($ thousand)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Rising global prevalence of refractory autoimmune hemolytic conditions drives demand
- Accelerated regulatory incentives for rare hematological treatments boost pipeline investments
- Expansion of precision medicine paradigms enables targeted complement pathway inhibition
- 13.2 Market challenges
- High clinical trial failure rates deter investment in novel targeted biologics
- Exorbitant annual treatment costs restrict patient access across diverse health systems
- Severe off-label corticosteroid dependency suppresses initial demand for specialized therapeutics
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 13.4 Market opportunities
- Strategic shift toward targeted complement pathway inhibitors reshapes standard paradigms
- Rising strategic collaborations between biotechnology leaders and academic research centers
- Integration of digital biomarkers and remote monitoring tools enhances trial efficiency
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 Annexon Biosciences Inc.
- Annexon Biosciences Inc. - Overview
- Annexon Biosciences Inc. - Product / Service
- Annexon Biosciences Inc. - Key offerings
- SWOT
- 15.5 Apellis Pharmaceuticals Inc.
- Apellis Pharmaceuticals Inc. - Overview
- Apellis Pharmaceuticals Inc. - Product / Service
- Apellis Pharmaceuticals Inc. - Key offerings
- SWOT
- 15.6 argenx SE
- argenx SE - Overview
- argenx SE - Product / Service
- argenx SE - Key offerings
- SWOT
- 15.7 AstraZeneca Plc
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Business segments
- AstraZeneca Plc - Key news
- AstraZeneca Plc - Key offerings
- AstraZeneca Plc - Segment focus
- SWOT
- 15.8 Aurinia Pharmaceuticals Inc.
- Aurinia Pharmaceuticals Inc. - Overview
- Aurinia Pharmaceuticals Inc. - Product / Service
- Aurinia Pharmaceuticals Inc. - Key offerings
- SWOT
- 15.9 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 15.10 Hutchison China Ltd.
- Hutchison China Ltd. - Overview
- Hutchison China Ltd. - Business segments
- Hutchison China Ltd. - Key offerings
- Hutchison China Ltd. - Segment focus
- SWOT
- 15.11 Incyte Corp.
- Incyte Corp. - Overview
- Incyte Corp. - Product / Service
- Incyte Corp. - Key news
- Incyte Corp. - Key offerings
- SWOT
- 15.12 Johnson and Johnson
- Johnson and Johnson - Overview
- Johnson and Johnson - Business segments
- Johnson and Johnson - Key news
- Johnson and Johnson - Key offerings
- Johnson and Johnson - Segment focus
- SWOT
- 15.13 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- 15.14 Nurix Therapeutics Inc.
- Nurix Therapeutics Inc. - Overview
- Nurix Therapeutics Inc. - Product / Service
- Nurix Therapeutics Inc. - Key offerings
- SWOT
- 15.15 Recordati S.p.A
- Recordati S.p.A - Overview
- Recordati S.p.A - Business segments
- Recordati S.p.A - Key offerings
- Recordati S.p.A - Segment focus
- SWOT
- 15.16 Rigel Pharmaceuticals Inc.
- Rigel Pharmaceuticals Inc. - Overview
- Rigel Pharmaceuticals Inc. - Product / Service
- Rigel Pharmaceuticals Inc. - Key offerings
- SWOT
- 15.17 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
- 15.18 Vertex Pharmaceuticals Inc.
- Vertex Pharmaceuticals Inc. - Overview
- Vertex Pharmaceuticals Inc. - Product / Service
- Vertex Pharmaceuticals Inc. - Key offerings
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
